StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho Defends Merck (MRK) on Weakness Related to Pfizer's Antiviral Drug
November 5, 2021 8:32 AM
Mizuho Securities analyst Mara Goldstein defended Merck (NYSE: MRK) following positive news on Pfizer's (NYSE: PFE) oral COVID-19 antiviral drug ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Trader Talk
Next Articles
Merck (MRK) and Ridgeback Announce Additional Purchase of 1.4M Courses of Molnupiravir by the US Government
November 9, 2021 6:04 AM
Merck (MRK) Acquisition of Acceleron Pharma Cleared by Antitrust Authorities in Germany and Austria
November 8, 2021 4:32 PM
Merck (MRK) ahead of Pfizer (PFE) in EU talks on COVID-19 pills -EU source - Reuters
November 8, 2021 11:15 AM
Pfizer (PFE) considering allowing generic makers to produce pill - Bloomberg
November 5, 2021 2:23 PM
Pfizer's (PFE) COVID Pill Best in Class, Will Put Pressure on Merck (MRK) and Regeneron (REGN) - Analyst
November 5, 2021 8:47 AM
Pfizer (PFE) Shares Surge 13% Following Game-Changing COVID-19 Pill Data, Merck (MRK) Down 9%; Analyst Sees Oral Antiviral Market Totaling 'Tens of Billion of Dollars Annually'
November 5, 2021 8:23 AM
Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%
November 5, 2021 6:59 AM
Pfizer (PFE) Surges 8%, Merck (MRK) Down 5% Following Pfizer's COVID-19 Oral Antiviral Treatment Data
November 5, 2021 6:49 AM
